Mucin alleviates colonic barrier dysfunction by promoting spermine accumulation through enhanced arginine metabolism

Xingjian Zhou1, Qian Xu1, Xiangyu Zhang1

  • 1State Key Laboratory of Animal Nutrition and Feeding, College of Animal Science and Technology, China Agricultural University, Beijing, China.

Msystems
|April 2, 2024
PubMed

Insights

Dietary mucin supplementation can restore gut barrier integrity by enhancing microbial spermine production. This process involves specific bacteria, like Limosilactobacillus mucosae, and their arginine metabolism, benefiting gut health.

Area of Science:

  • Microbiology
  • Gastroenterology
  • Nutritional Science

Background:

  • Dietary fiber deprivation disrupts the gut barrier and probiotic balance.
  • Mucin's role in rescuing these defects is largely unknown.
  • Microbial polyamines, like spermine, can support intestinal health.

Purpose of the Study:

  • To investigate how exogenous mucin maintains gut barrier function.
  • To elucidate the mechanism by which mucin influences microbial metabolites and gut health.
  • To identify specific microbes and metabolic pathways involved.

Main Methods:

  • In vivo studies using dietary mucin supplementation.
  • In vitro models to study microbial interactions with mucin.
  • Identification of specific bacterial strains and their metabolic activities.
  • Analysis of polyamine production and its impact on gut barrier markers.

Main Results:

  • Dietary mucin alleviated fiber deprivation-induced colonic barrier defects.
  • Mucin supplementation increased microbial-derived spermine production, linked to increased Lactobacillus abundance.
  • Limosilactobacillus mucosae was identified as a key spermine producer, especially when adhering to mucin.
  • Bacterial supernatant from L. mucosae enhanced barrier function via spermine and arginine metabolism.

Conclusions:

  • Mucin supplementation can restore gut barrier integrity by modulating microbial arginine metabolism.
  • Microbial-derived spermine plays a crucial role in mediating mucin's beneficial effects on the gut barrier.
  • This highlights a novel mechanism linking dietary mucin, microbial metabolites, and host gut health.

Related Concept Videos

Mucosal Barrier of the Stomach01:25

Mucosal Barrier of the Stomach

The gastric glands contain parietal cells that secrete hydrochloric acid (HCl) for digestion. The cells secrete HCl because it is highly corrosive and essential for breaking down food. To achieve this, they secrete hydrogen and chloride ions into the lumen of the gastric glands, which combine to form HCl.
Within parietal cells, carbonic acid is first formed through the reaction of water and carbon dioxide. The dissociation of carbonic acid releases bicarbonate and hydrogen ions. The bicarbonate...
649
Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents01:24

Drugs for Peptic Ulcer Disease: Sucralfate as Mucosal Protective Agents

In the intricate landscape of the gastric lumen, excessive acid secretion disrupts the natural defense mechanisms, weakening the mucus-bicarbonate barrier. This vulnerability allows pepsin to infiltrate epithelial cells, digesting mucosal proteins and triggering erosion, leading to ulcer formation.
In this scenario, mucosal protective agents like sucralfate play an essential role. Sucralfate, a complex of sulfated sucrose and aluminum hydroxide, demonstrates its usefulness in acidic conditions,...
479
Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors01:24

Pathophysiology of Peptic Ulcer Disease: Mucosal Defense Factors

Peptic ulcer disease, commonly called PUD, represents a multifaceted condition characterized by disruptions in the lining of the gastrointestinal (GI)  tract. Central to the protection of the gastrointestinal lining is the mucosal-bicarbonate barrier. This physiological defense mechanism is a formidable shield against the corrosive effects of gastric acid and pepsin secretion in the stomach. Its role is pivotal in maintaining the structural integrity of the stomach's inner lining.
409
Drugs for Treatment of Constipation-Predominant IBS01:21

Drugs for Treatment of Constipation-Predominant IBS

Pharmacological therapies for IBS-C are designed to alleviate abdominal discomfort and enhance bowel function. In patients with IBS-C, fiber supplements may help soften stools and decrease straining, but may also lead to increased gas production and bloating. Osmotic laxatives like milk of magnesia are frequently used to soften stools and increase stool frequency in IBS-C patients. In addition, two drugs approved for use in severe IBS-C adult cases are linaclotide (Linzess) and lubiprostone...
162
Drugs for Treatment of Ulcerative Colitis in IBD01:29

Drugs for Treatment of Ulcerative Colitis in IBD

Ulcerative colitis is a chronic inflammatory condition primarily affecting the colon and rectum. The primary drugs used in the treatment of ulcerative colitis are aminosalicylates. They exhibit anti-inflammatory and immunosuppressive properties. They modulate inflammatory mediators and inhibit the activity of nuclear factor κB (NF-κB). Aminosalicylates also reduce inflammation by inhibiting prostaglandin and leukotriene production and decreasing neutrophil chemotaxis and superoxide...
138
Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents01:20

Drugs for Peptic Ulcer Disease: Prostaglandin Analogs as Mucosal Protective Agents

The gastric mucosa produces prostaglandins E2 (PGE2) and prostacyclin (PGI2), crucial in maintaining gastric health. They exert cytoprotective effects, including increasing bicarbonate secretion, releasing protective mucin, reducing gastric acid output, and preventing harmful vasoconstriction. These effects are mediated through various receptors, such as EP1, EP2, EP3, and EP4.
Non-steroidal anti-inflammatory drugs (NSAIDs) can induce peptic ulcers by inhibiting cyclooxygenase, decreasing...
428